comparemela.com

Latest Breaking News On - Ankylosing spondylitis disease activity score - Page 8 : comparemela.com

Study Supports Bimekizumab for Nonradiographic Axial Spondyloarthritis

Positive results from a phase 3 study evaluating bimekizumab in adults with active non-radiographic axial spondyloarthritis.

Emmanuel caeymaexImmunology solutionsDrug administrationAssessment of spondyloarthritis international societySpondyloarthritis international societyAnkylosing spondylitis disease activity scoreExecutive vice presidentBiologics license application

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

BRUSSELS and ATLANTA, Jan. 18, 2022 /PRNewswire/ UCB, a global biopharmaceutical company, today announced positive top-line interim analysis re.

United statesBruxelles capitaleEmmanuel caeymaexAntje witteImmunology solutionsBrand communicationsDrug administrationCorporate communications nicole hergaDivision of arthritisBrand communications eimear obrienAssessment of spondyloarthritis international societyEuropean unionOregon health science universitySpondyloarthritis international societyAnkylosing spondylitis disease activity scoreMajor improvement

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

/PRNewswire/ UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study.

United statesUnited kingdomBruxelles capitaleNicole hergaEmmanuel caeymaexMusculoskelet disordEimear obrienAntje witteJ clin pharmacolImmunology solutionsBrand communicationsDrug administrationDivision of arthritisAssessment of spondyloarthritis international societyEuropean unionCorporate communications

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

/PRNewswire/ UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study.

United statesUnited kingdomBruxelles capitaleNicole hergaEmmanuel caeymaexMusculoskelet disordEimear obrienAntje witteJ clin pharmacolImmunology solutionsBrand communicationsDrug administrationDivision of arthritisAssessment of spondyloarthritis international societyEuropean unionCorporate communications

Significant Improvements Seen With Bimekizumab in Ankylosing Spondylitis Trial

The ongoing phase 3 BE MOBILE 2 study compared the efficacy and safety of bimekizumab to placebo in 332 adults with active ankylosing spondylitis.

Emmanuel caeymaexImmunology solutionsDrug administrationAssessment of spondyloarthritis international societySpondyloarthritis international societyAnkylosing spondylitis disease activity scoreExecutive vice presidentBiologics license application

vimarsana © 2020. All Rights Reserved.